Microbiome-based biomarkers and models of lung cancer development and treatment

基于微生物组的肺癌发展和治疗的生物标志物和模型

基本信息

批准号：
10739531
负责人：
William Evan Johnson
金额：
$ 14.56万
依托单位：
RUTGERS BIOMEDICAL AND HEALTH SCIENCES
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-12-01 至 2024-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10739531
关键词：
Age Antibiotics Binding Biological Markers Cancer Detection Cancer Intervention Child Chronic Obstructive Pulmonary Disease Communities Computer Models Data Databases Development Diabetes Mellitus Diagnostic Equilibrium Etiology Experimental Models Future Gene Expression Genome Health Human Immune response Immunity Individual Inflammatory Intervention Link Location Malignant Neoplasms Malignant neoplasm of lung Metabolism Microbe Military Personnel Modeling Nose Obesity Oncogenic Outcome Pathway interactions Play Prevention Process Publishing Research Role Sampling Severities Smoking Status System Taxonomy Testing Transplantation Validation Work anticancer research asthmatic cancer biomarkers cancer immunotherapy cancer prevention cancer therapy candidate marker comorbidity design former smoker genome-wide host-microbe interactions human disease improved interest lung cancer prevention lung cancer screening lung tumorigenesis machine learning algorithm metatranscriptomics microbial microbial community microbiome microbiome composition microbiome research microbiota transplantation microorganism interaction nasal microbiome nasal microbiota novel strategies pathogen predictive marker predictive modeling receptor screening sex targeted treatment transcriptome sequencing transcriptomics tumor progression

项目摘要

Project Summary/Abstract The microbiome has become an important focus of cancer research, including its role in prevention, diagnostics, and mechanistic causation. However, there are still significant gaps in our understanding of the mechanisms and molecular interactions (both microbe-microbe and microbe-host) that continue to hinder our abilities to develop effective microbiome-based biomarkers for cancer outcomes or for using the microbiome as a target for cancer treatment or prevention. For lung cancer there has been some recent progress studying the mechanistic role of the microbiome in lung tumorigenesis, although lung cancer microbiome research has lagged behind progress in other cancers. Here we propose to use RNA-sequencing data from nasal samples of current and former smokers in combination with state-of-the art computational modeling to develop effective biomarkers and explore the role of microbe- microbe and microbe-host interactions in lung cancer. We will first develop and validate predictive biomarkers for lung cancer using the microbiome and host gene expression. In the process, we will also characterize microbe-microbe interactions associated with cancer status, and evaluate microbiome interactions with human oncogenic and inflammatory pathways. We will also develop predictive models for assessing the impact of host and microbial targeted therapies, as well as the impact of the transplantation of individual microbes or synthetic communities.

项目摘要/摘要微生物组已成为癌症研究的重要重点，包括其在预防，诊断，和机械因果关系。但是，我们对机制的理解仍然存在很大的差距分子相互作用（微生物微生物和微生物宿主），这些相互作用继续阻碍我们发展的能力有效的基于微生物组的生物标志物用于癌症结果或使用微生物组作为癌症的靶标治疗或预防。对于肺癌，最近有一些进步研究尽管肺癌微生物组研究落后于肺癌，但肺肿瘤发生的微生物组却落后于进展在其他癌症中。在这里，我们建议使用当前和以前吸烟者的鼻样品中的RNA测序数据使用最先进的计算建模来开发有效的生物标志物并探索微生物的作用肺癌中的微生物和微生物宿主相互作用。我们将首先开发并验证预测性生物标志物使用微生物组和宿主基因表达进行肺癌。在此过程中，我们还将表征与癌症状态相关的微生物微生物相互作用，并评估与人类的微生物组相互作用致癌和炎症途径。我们还将开发用于评估主机影响的预测模型和微生物靶向疗法，以及单个微生物移植或合成的影响社区。